Zydus Lifesciences’ arm acquires worldwide proprietary rights to Zokinvy

04 May 2024 Evaluate

Zydus Lifesciences’ wholly owned subsidiary -- Sentynl Therapeutics Inc., USA, (Sentynl) has acquired worldwide proprietary rights to Zokinvy (lonafarnib) from Eiger Biopharmaceuticals Inc., USA (Seller), pursuant to an asset purchase agreement (APA), adding to portfolio of biopharmaceuticals for rare and ultra-rare diseases. 

Zokinvy is approved in the U.S. (2020), European Union and Great Britain (2022), and Japan (2024) for the treatment of Progeria, a collection of ultra-rare, fatal, genetic premature aging diseases that accelerate mortality in young patients. 

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.


Zydus Lifesciences Share Price

1104.45 52.55 (5.00%)
18-May-2024 12:50 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1532.85
Dr. Reddys Lab 5812.50
Cipla 1403.90
Zydus Lifesciences 1104.45
Lupin 1661.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.